112 related articles for article (PubMed ID: 38905803)
1. Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer.
Zhan T; Dai J; Li Y
Eur J Radiol; 2024 Jun; 177():111573. PubMed ID: 38905803
[TBL] [Abstract][Full Text] [Related]
2. Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models.
Mao C; Hu L; Jiang W; Qiu Y; Yang Z; Liu Y; Wang M; Wang D; Su Y; Lin J; Yan X; Cai Z; Zhang X; Shen J
Eur Radiol; 2024 Apr; 34(4):2546-2559. PubMed ID: 37672055
[TBL] [Abstract][Full Text] [Related]
3. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics.
Zheng S; Yang Z; Du G; Zhang Y; Jiang C; Xu T; Li B; Wang D; Qiu Y; Lin D; Zhang X; Shen J
Eur Radiol; 2024 Feb; ():. PubMed ID: 38363315
[TBL] [Abstract][Full Text] [Related]
4. Investigation of synthetic MRI with quantitative parameters for discriminating axillary lymph nodes status in invasive breast cancer.
Qu M; Feng W; Liu X; Li Z; Li Y; Lu X; Lei J
Eur J Radiol; 2024 Jun; 175():111452. PubMed ID: 38604092
[TBL] [Abstract][Full Text] [Related]
5. Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status.
Li X; Fan Z; Jiang H; Niu J; Bian W; Wang C; Wang Y; Zhang R; Zhang H
Sci Rep; 2023 Oct; 13(1):17978. PubMed ID: 37864025
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the added value of synthetic magnetic resonance imaging in predicting sentinel lymph node status in breast cancer.
Yang X; Lu Z; Tan X; Shao L; Shi J; Dou W; Sun Z
Quant Imaging Med Surg; 2024 Jun; 14(6):3789-3802. PubMed ID: 38846281
[TBL] [Abstract][Full Text] [Related]
7. Whole-tumor histogram models based on quantitative maps from synthetic MRI for predicting axillary lymph node status in invasive ductal breast cancer.
Zeng F; Yang Z; Tang X; Lin L; Lin H; Wu Y; Wang Z; Chen M; Chen L; Chen L; Wu PY; Wang C; Xue Y
Eur J Radiol; 2024 Mar; 172():111325. PubMed ID: 38262156
[TBL] [Abstract][Full Text] [Related]
8. Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer.
Bian X; Du S; Yue Z; Gao S; Zhao R; Huang G; Guo L; Peng C; Zhang L
J Magn Reson Imaging; 2023 Nov; 58(5):1603-1614. PubMed ID: 36763035
[TBL] [Abstract][Full Text] [Related]
9. [Differential diagnosis of benign and malignant breast lesions using quantitative synthetic magnetic resonance imaging].
Zhang L; Zhao X; Yin X
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):457-462. PubMed ID: 35527481
[TBL] [Abstract][Full Text] [Related]
10. Synthetic MRI and diffusion-weighted imaging for differentiating nasopharyngeal lymphoma from nasopharyngeal carcinoma: combination with morphological features.
Zhang H; Hu L; Qin F; Chang J; Zhong Y; Dou W; Hu S; Wang P
Br J Radiol; 2024 Jun; 97(1159):1278-1285. PubMed ID: 38733577
[TBL] [Abstract][Full Text] [Related]
11. Predicting of Ki-67 Expression Level Using Diffusion-Weighted and Synthetic Magnetic Resonance Imaging in Invasive Ductal Breast Cancer.
Zhang L; Hao J; Guo J; Zhao X; Yin X
Breast J; 2023; 2023():6746326. PubMed ID: 37063453
[TBL] [Abstract][Full Text] [Related]
12. [The value of synthetic MRI in differential diagnosis of benign and malignant breast lesions].
Che SN; Li J; Xue M; Song Y; Zhao LY; Guo N; Tian Y; Xie LZ; Zhao XM; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):872-877. PubMed ID: 34407594
[No Abstract] [Full Text] [Related]
13. Radiomics analysis of intratumoral and different peritumoral regions from multiparametric MRI for evaluating HER2 status of breast cancer: A comparative study.
Zhou J; Yu X; Wu Q; Wu Y; Fu C; Wang Y; Hai M; Tan H; Wang M
Heliyon; 2024 Apr; 10(7):e28722. PubMed ID: 38623231
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer.
Peng Y; Zhang X; Qiu Y; Li B; Yang Z; Huang J; Lin J; Zheng C; Hu L; Shen J
AJR Am J Roentgenol; 2024 Apr; 222(4):e2330603. PubMed ID: 38265001
[No Abstract] [Full Text] [Related]
15. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers.
Ramtohul T; Djerroudi L; Lissavalid E; Nhy C; Redon L; Ikni L; Djelouah M; Journo G; Menet E; Cabel L; Malhaire C; Tardivon A
Radiology; 2023 Aug; 308(2):e222646. PubMed ID: 37526540
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic performance of quantitative mapping in breast cancer patients: a preliminary study using synthetic MRI.
Meng T; He N; He H; Liu K; Ke L; Liu H; Zhong L; Huang C; Yang A; Zhou C; Qian L; Xie C
Cancer Imaging; 2020 Dec; 20(1):88. PubMed ID: 33317609
[TBL] [Abstract][Full Text] [Related]
17. Application of synthetic magnetic resonance imaging and DWI for evaluation of prognostic factors in cervical carcinoma: a prospective preliminary study.
Zhang W; Lu N; He H; Liu H; Zhu F; Ma L; Luo Y; Qian L; Meng T; Xie C
Br J Radiol; 2023 Jan; 96(1141):20220596. PubMed ID: 36341699
[TBL] [Abstract][Full Text] [Related]
18. Synthetic MRI and amide proton transfer-weighted MRI for differentiating between benign and malignant sinonasal lesions.
Xiang Y; Zhang Q; Chen X; Sun H; Li X; Wei X; Zhong J; Gao B; Huang W; Liang W; Sun H; Yang Q; Ren X
Eur Radiol; 2024 Mar; ():. PubMed ID: 38491129
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Parameters of Diffusion Spectrum Imaging: HER2 Status Prediction in Patients With Breast Cancer.
Mao C; Jiang W; Huang J; Wang M; Yan X; Yang Z; Wang D; Zhang X; Shen J
Front Oncol; 2022; 12():817070. PubMed ID: 35186753
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric MRI model with synthetic MRI, DWI multi-quantitative parameters, and differential sub-sampling with cartesian ordering enables BI-RADS 4 lesions diagnosis with high accuracy.
He H; Song M; Tian Z; Gao N; Ma J; Wang Z
Front Oncol; 2023; 13():1180131. PubMed ID: 38250550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
